...
首页> 外文期刊>Cerebrovascular diseases >Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment.
【24h】

Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment.

机译:Ca拮抗剂尼伐地平对有或没有中风病史的高血压患者中风发生或无症状性脑梗死的复发和扩展的影响(PICA研究)。 1.入学时的设计和结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: We examined the effect of a Ca antagonist (nilvadipine) on the occurrence or recurrence of symptomatic stroke in hypertensive patients with MRI-defined asymptomatic cerebral infarction (ACI), periventricular hyperintensity (PVH), and deep and subcortical white matter hyperintensity (DSWMH), with or without a history of stroke, and evaluated the effect of long-term treatment on the lesions. METHODS: Patients with hypertension and incidental ACI were divided into those with (group B, 235 patients) or without (group A, 181 patients) a history of symptomatic stroke, and were given nilvadipine 4-8 mg/day for 3 years. Primary evaluation points were occurrence of symptomatic ischemic stroke and development or extension of asymptomatic ischemic lesions. RESULTS: Male sex, hyperuricemia, diabetes, maximum diameter of infarction and PVH severity were stronger risk factors for group B. Numbers of cerebral infarctions were 31 +/- 28 (group A) and 42 +/- 32 (group B) at enrollment (p < 0.001). Infarctions were larger and located more frequently on the internal capsule, putamen, thalamus and brainstem in group B. The severity of PVH and DSWMH paralleled the number of cerebral infarctions in both groups. CONCLUSION: The study design and status of asymptomatic ischemic brain lesions in hypertensive subjects at enrollment are presented.
机译:背景:我们检查了钙拮抗剂(尼伐地平)对有MRI定义的无症状性脑梗死(ACI),室周性高血压(PVH),深部和皮质下白质亢进(DSWMH)的高血压患者症状性中风的发生或复发的影响。 )(有无中风病史),并评估了长期治疗对病变的作用。方法:将高血压和偶发ACI患者分为有症状性中风病史(B组235例)或无症状(A组181例),并给予尼伐地平4-8 mg /天,治疗3年。主要评估点是有症状缺血性中风的发生和无症状缺血性病变的发展或扩展。结果:男性,高尿酸血症,糖尿病,最大梗死直径和PVH严重程度是B组的更强危险因素。入组时脑梗死的数目为31 +/- 28(A组)和42 +/- 32(B组) (p <0.001)。 B组梗死面积更大,更常见于内囊,壳核,丘脑和脑干。PVH和DSWMH的严重程度与两组脑梗死的数量平行。结论:提出了高血压患者无症状缺血性脑损伤的研究设计和现状。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号